Article info

other Versions

PDF
Extended report
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Authors

  1. Correspondence to Dr Renee S Martin, Anthera Pharmaceuticals, Inc, Hayward, California 94545, USA; rmartin{at}anthera.com
View Full Text

Citation

Merrill JT, Shanahan WR, Scheinberg M, et al
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Publication history

  • Received January 16, 2018
  • Revised March 1, 2018
  • Accepted March 2, 2018
  • First published March 21, 2018.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.